YL Biologics
Tokyo, Japan· Est.
YL Biologics develops and commercializes high-quality biosimilar drugs to reduce healthcare costs and improve patient access to biologic therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
YL Biologics develops and commercializes high-quality biosimilar drugs to reduce healthcare costs and improve patient access to biologic therapies.
HematologyNephrologyOncology
Technology Platform
Biosimilar development platform focusing on analytical characterization, process development, and manufacturing of biologic therapeutics to demonstrate similarity to reference products.
Opportunities
Growing global biosimilars market driven by cost containment pressures, with potential to expand pipeline beyond erythropoiesis stimulating agents to other therapeutic biologic categories.
Risk Factors
Regulatory hurdles for biosimilar approval, competition from originator products and other biosimilar developers, and pricing pressures in the biosimilars market.
Competitive Landscape
Competes against originator biologic manufacturers (Amgen's Aranesp) and other biosimilar developers in the erythropoiesis stimulating agent market, differentiating through Japan-India partnership and quality focus.